Clinical trial
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil…
NCT00046683 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00046683 |
|---|---|
| Title | Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia |
| Official title | A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | B Cell Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | alemtuzumab |
| Enrollment | 284 |
| Start date | Jul 1, 2001 |
| Completion | Jun 1, 2006 |
| First posted | Oct 2, 2002 |
| Last update posted | Jul 28, 2016 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: